`

Table of Contents for Supplementary Appendix 2

`

Site Name in United Kingdom	Primary Investigator
Altnagelvin Hospital	Dr Frank McCarroll
Antrim Area Hospital	Dr Stephanie Bolton
Birmingham Heartlands Hospital	Dr Stephen John
Bradford, St Luke's	Dr Habib Akbani
City Hospital, Nottingham	Dr Simon Roe
Colchester General Hospital	Dr Gabor Cserep
Coventry, University Hospital Coventry	Dr Waqar Ayub
Daisy Hill Hospital, Newry	Dr Neal Morgan
Doncaster Royal Infirmary	Dr Muhammad Kanaa
Dorset County Hospital	Dr Jo Taylor
Glan Clwyd Hospital	Dr Hemakumar Mallappa
Gloucestershire Royal Hospital	Dr Jim Moriarty
Huddersfield / Calderdale Royal Hospital	Dr Victoria Briggs
Hull University Teaching Hospitals NHS Trust	Prof Sunil Bhandari
Imperial College London, Charing Cross	Prof Edwina Brown
Kent and Canterbury Hospital	Dr Nasir Abbas
King's College Hospital	Dr Martin Ford
Leicester General Hospital	Dr Peter Topham
Lister Hospital	Dr Shahid Chandna
Manchester Royal Infirmary	Prof Sandip Mitra
Morriston Hospital	Dr Ashraf Mikhail
New Cross Hospital, Wolverhampton	Dr Kanwaljit Sandhu
Northern General (Sheffield)	Dr Arif Khwaja
Queen Alexandra Hospital (Portsmouth)	Dr Mark Uniacke
Queen Elizabeth Hospital Birmingham	Prof Paul Cockwell
Queen's Hospital Romford	Dr Nasreen Samad
Royal Free Hospital (London)	Prof David Wheeler
Royal Liverpool University Hospital	Dr Muhammad Ahmed
Royal Preston Hospital	Dr Aimun Ahmed
Royal Shrewsbury Hospital	Dr Ramaswamy Diwakar
Royal Sussex County Hospital	Dr Laurie Tomlinson
Salford Royal Hospital	Dr Edmond O'Riordan
Southend University Hospital	Dr Gowrie Balasubramaniam
St Helier Hospital	Dr Rebecca Suckling
St James's University Hospital (Leeds)	Dr Andrew Mooney
Sunderland Royal Hospital	Dr Saeed Ahmed
York Teaching Hospitals NHS Trust	Dr Donald Richardson

`

Trial Steering Committee (TSC)

The independent members of the TSC are: Dr Richard Haynes (Consultant Nephrologist; chair); Dr Nick Selby (Consultant Nephrologist); and Christopher Allison (Patient Representative).

Independent Data Monitoring Committee

The independent members of the DMC are: Dr John Firth (Consultant Nephrologist; chair); Dr Paul Kalra (Consultant Cardiologist); and Mrs Merryn Voysey (Statistician).

Birmingham Clinical Trial Unit

Jon Bishop, Elizabeth Brettell, Marie Chadburn, Jamie Godsall, Nick Hilken, Charmaine Hunt, Natalie Ives, Hugh Jarrett, Aisha Khan, Alastair Maund, Samir Mehta, Neil Winkles.

`

Figure S1: Least Squares means plot (Sensitivity analysis (CKD-EPI equation 2009))



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S2: Least Squares means plot (Sensitivity analysis (4-MDRD$_{186}$ equation))



Note:

- eGFR values after commencing Kidney replacement therapy (i.e. dialysis/transplant) are not included in the analysis.

`

Figure S3: Least Squares means plot (Pattern Mixture Model (PMM) Flat value 5ml/min/1.73m^2 imputation - 4-MDRD$_{175}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S4: Least Squares means plot (Pattern mixture Model (PMM) Flat value 5ml/min/1.73m^2 imputation – CKD-EPI equation 2009)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S5: Least Squares means plot (Pattern Mixture Model (PMM) Flat value 5ml/min/1.73m^2 imputation – 4-MDRD$_{186}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S6: Least Squares means plot (Pattern Mixture Model (PMM) Flat value 7ml/min/1.73m^2 imputation - 4-MDRD$_{175}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S7: Least Squares means plot (Pattern Mixture Model (PMM) Flat value 7ml/min/1.73m^2 imputation – CKD-EPI equation 2009)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S8: Least Squares means plot (Pattern Mixture Model (PMM)L Flat value 7ml/min/1.73m^2 imputation – 4-MDRD$_{186}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S9: Least Squares means plot (Pattern Mixture Model (PMM) Last Observation Carried Forward (LOCF) imputation – 4-MDRD$_{175}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S10: Least Squares means plot (Pattern mixture model of Last Observation Carried Forward imputation – CKD-EPI equation 2009)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S11: Least Squares means plot (Pattern mixture model Last Observation Carried Forward imputation – 4-MDRD$_{186}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S12: Joint model plot of eGFR data (4-MDRD$_{175}$ equation)



*Event=participants that had a Kidney replacement therapy (i.e. dialysis or transplant) or reached ESKD.
Time scale is adjusted by taking away participant's survival time.

`

Figure S13: Least Squares means plot - Joint model (4-MDRD$_{175}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S14: Joint model plot of eGFR data (CKD-EPI equation 2009)



*

Event=participants that had a Kidney replacement therapy (i.e. dialysis or transplant) or reached ESKD.
Time scale is adjusted by taking away participant's survival time.

`

Figure S15: Least Squares means plot - Joint model (CKD-EPI equation 2009)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Figure S16: Joint model plot of eGFR data (4-MDRD$_{186}$ equation)



*Event=participants that had a Kidney replacement therapy (i.e. dialysis or transplant) or reached ESKD.
Time scale is adjusted by taking away participant's survival time.

`

Figure S17: Least Squares means plot - Joint model (4-MDRD$_{186}$ equation)



Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Table S1: Sensitivity analysis (CKD-EPI equation 2009)

	Time point	Summary Statistic	STOP	Continue	Mixed-effects linear regression Est. Mean Diff (95% CI)* P-value
eGFR (mL/min/1.73m^2)	3 months	N Empirical Mean [SD] LS-Mean ± [SE]	187 16.9 [6.5] 18.62 ± [0.26]	190 16.9 [6] 18.58 ± [0.29]	-
	6 months	N Empirical Mean [SD] LS-Mean ± [SE]	166 16.3 [6.5] 17.31 ± [0.29]	172 16.6 [6.7] 18.02 ± [0.33]	-
	9 months	N Empirical Mean [SD] LS-Mean ± [SE]	148 16.2 [6.4] 16.42 ± [0.32]	157 16.7 [6.3] 17.25 ± [0.31]	-
	12 months	N Empirical Mean [SD] LS-Mean ± [SE]	130 16.1 [6.4] 15.78 ± [0.36]	142 16.4 [6.7] 16.44 ± [0.36]	-
	15 months	N Empirical Mean [SD] LS-Mean ± [SE]	117 15.9 [6.4] 14.89 ± [0.37]	122 16 [6.3] 15.89 ± [0.38]	-
	18 months	N Empirical Mean [SD] LS-Mean ± [SE]	100 16.3 [6.7] 14.56 ± [0.43]	108 17.2 [6.2] 15.69 ± [0.40]	-
	21 months	N Empirical Mean [SD] LS-Mean ± [SE]	96 16.1 [6.8] 14.08 ± [0.48]	99 16.8 [6.3] 15.28 ± [0.43]	-
	24 months	N Empirical Mean [SD] LS-Mean ± [SE]	88 15.7 [7.3] 13.09 ± [0.54]	95 16.3 [5.5] 14.16 ± [0.40]	-
	27 months	N Empirical Mean [SD] LS-Mean ± [SE]	78 15.6 [7.1] 13.00 ± [0.54]	87 15.5 [5.5] 13.45 ± [0.50]	-
	30 months	N Empirical Mean [SD] LS-Mean ± [SE]	69 15.7 [7.5] 12.36 ± [0.59]	80 15.7 [7] 13.42 ± [0.63]	-
	33 months	N Empirical Mean [SD] LS-Mean ± [SE]	59 15.7 [7.9] 11.85 ± [0.65]	66 15.9 [6.4] 13.05 ± [0.55]	-
	36 months	N Empirical Mean [SD] LS-Mean ± [SE]	**56** **16.4 [8.2]** **12.04 ± [0.69]**	**69** **16.1 [7.1]** **12.79 ± [0.61]**	**-0.75 (-2.53, 1.02)**

*Adjusted for minimisation variables (age, eGFR, proteinuria, MAP, diabetes), time-point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust standard errors used. Continue group used as reference category in the model and values >0 indicate better outcome for STOP group. LS-Mean=Least squares mean; SE=Standard Error

Note: eGFR values after commencing Kidney replacement therapy (i.e. dialysis/transplant) are not included in the analysis. Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Table S2: Sensitivity analysis (4-MDRD$_{186}$ equation)

	Time point	Summary Statistic	STOP	Continue	Mixed-effects linear regression
					Est. Mean Diff (95% CI)* P-value
eGFR (mL/min/1.73m^2)	3 months	N Empirical Mean [SD] LS-Mean ± [SE]	187 16.9 [6.5] 20.02 ± [0.27]	190 16.9 [6] 19.94 ± [0.30]	-
	6 months	N Empirical Mean [SD] LS-Mean ± [SE]	166 16.3 [6.5] 18.68 ± [0.30]	172 16.6 [6.7] 19.38 ± [0.35]	-
	9 months	N Empirical Mean [SD] LS-Mean ± [SE]	148 16.2 [6.4] 17.76 ± [0.33]	157 16.7 [6.3] 18.61 ± [0.33]	-
	12 months	N Empirical Mean [SD] LS-Mean ± [SE]	130 16.1 [6.4] 17.13 ± [0.37]	142 16.4 [6.7] 17.77 ± [0.38]	-
	15 months	N Empirical Mean [SD] LS-Mean ± [SE]	117 15.9 [6.4] 16.23 ± [0.39]	122 16 [6.3] 17.24 ± [0.40]	-
	18 months	N Empirical Mean [SD] LS-Mean ± [SE]	100 16.3 [6.7] 15.90 ± [0.45]	108 17.2 [6.2] 17.06 ± [0.42]	-
	21 months	N Empirical Mean [SD] LS-Mean ± [SE]	96 16.1 [6.8] 15.40 ± [0.50]	99 16.8 [6.3] 16.65 ± [0.45]	-
	24 months	N Empirical Mean [SD] LS-Mean ± [SE]	88 15.7 [7.3] 14.42 ± [0.57]	95 16.3 [5.5] 15.52 ± [0.42]	-
	27 months	N Empirical Mean [SD] LS-Mean ± [SE]	78 15.6 [7.1] 14.31 ± [0.56]	87 15.5 [5.5] 14.79 ± [0.52]	-
	30 months	N Empirical Mean [SD] LS-Mean ± [SE]	69 15.7 [7.5] 13.64 ± [0.62]	80 15.7 [7] 14.75 ± [0.66]	-
	33 months	N Empirical Mean [SD] LS-Mean ± [SE]	59 15.7 [7.9] 13.14 ± [0.68]	66 15.9 [6.4] 14.41 ± [0.57]	-
	36 months	N Empirical Mean [SD] LS-Mean ± [SE]	**56** **16.4 [8.2]** **13.35 ± [0.72]**	**69** **16.1 [7.1]** **14.12 ± [0.64]**	**-0.77 (-2.63, 1.10)**

*Adjusted for minimisation variables (age, eGFR, proteinuria, MAP, diabetes), time-point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust standard errors used. Continue group used as reference category in the model and values >0 indicate better outcome for STOP group. LS-Mean=Least squares mean; SE=Standard Error

Note: eGFR values after commencing Kidney replacement therapy (i.e. dialysis/transplant) are not included in the analysis. And Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Table S3: Pattern Mixture Model results at 3 years' time-point

Pattern Mixture Model	eGFR Equation	Imputation	Summary Statistic	STOP	Continue	Mixed-effects linear regression
						Estimated Mean Diff (95% CI)* At 3 years
eGFR (mL/min/1.73m^2)	$MDRD_{175}$	Flat value 5ml/min	LS-Mean ± [SE] at 3 years	9.38 ± [0.43]	9.91 ± [0.42]	-0.54 (-1.72, 0.65)
		Flat value 7ml/min		10.56 ± [0.41]	10.99 ± [0.38]	-0.43 (-1.53, 0.66)
		LOCF		12.11 ± [0.38]	12.52 ± [0.37]	-0.41 (-1.45, 0.63)
	CKD-EPI	Flat value 5ml/min		9.19 ± [0.43]	9.63 ± [0.41]	-0.43 (-1.61, 0.75)
		Flat value 7ml/min		10.37 ± [0.41]	10.70 ± [0.38]	-0.33 (-1.42, 0.76)
		LOCF		11.77 ± [0.39]	12.15 ± [0.37]	-0.38 (-1.43, 0.68)
	$MDRD_{186}$	Flat value 5ml/min		9.78 ± [0.47]	10.37 ± [0.45]	-0.59 (-1.87, 0.69)
		Flat value 7ml/min		10.96 ± [0.44]	11.44 ± [0.41]	-0.48 (-1.67, 0.70)
		LOCF		12.84 ± [0.41]	13.28 ± [0.39]	-0.44 (-1.54, 0.66)

*Adjusted for minimisation variables (age, eGFR, proteinuria, Mean Arterial Pressure, diabetes), time-point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust standard errors used. Continue group used as reference category in the model and values >0 indicate better outcomes for STOP group.

LOCF=Last observation carried forward; LS-Mean=Least squares mean; SE=Standard Error

Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

`

Table S4: Joint Model results at 3 years' time-point

Joint Model	eGFR Equation	Summary Statistic	STOP	Continue	Joint model	
					Estimated Mean Diff (95% CI)* At 3 years	Hazard Ratio (95% CI)$
eGFR ($mL/min/1.73m^2$)	$MDRD_{175}$	LS-Mean ± [SE] at 3 years	12.17 ± [0.45]	12.99 ± [0.42]	-0.82 (-2.01, 0.37)	1.41 (0.93, 2.12)
	CKD-EPI		11.63 ± [0.46]	12.49 ± [0.43]	-0.85 (-2.07, 0.36)	1.40 (0.93, 2.10)
	$MDRD_{186}$		12.93 ± [0.48]	13.80 ± [0.44]	-0.87 (-2.13, 0.39)	1.41 (0.93, 2.12)

*Adjusted for minimisation variables (age, eGFR, proteinuria, Mean Arterial Pressure, diabetes), time-point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust standard errors used. Continue group used as reference category in the model and values >0 indicate better outcomes for STOP group.

$-Adjusted for minimisation variables (age, eGFR, proteinuria, MAP, diabetes).

LOCF=Last observation carried forward; LS-Mean=Least squares mean; SE=Standard Error

Note:

- Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.